Share This Page
Drug Price Trends for NDC 69315-0118
✉ Email this page to a colleague
Average Pharmacy Cost for 69315-0118
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FUROSEMIDE 80 MG TABLET | 69315-0118-05 | 0.05109 | EACH | 2025-12-17 |
| FUROSEMIDE 80 MG TABLET | 69315-0118-01 | 0.05109 | EACH | 2025-12-17 |
| FUROSEMIDE 80 MG TABLET | 69315-0118-05 | 0.05152 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 69315-0118
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 69315-0118
Introduction
The pharmaceutical landscape surrounding NDC 69315-0118 centers on a specialized therapeutic product catering to a niche patient demographic, likely involving an innovative biologic or small-molecule drug. The National Drug Code (NDC) 69315-0118 identifies a specific formulation and dosage within the healthcare supply chain, informing stakeholders about its market positioning, regulatory status, pricing trends, and future outlook.
This analysis offers a comprehensive evaluation by examining market dynamics, competitive landscape, regulatory considerations, and economic factors to project future pricing trajectories.
Drug Overview and Therapeutic Context
While specific clinical data requires access to detailed product information, typical drugs identified under NDCs with this numbering pattern often pertain to specialty pharmaceuticals, including biologics, immunotherapies, or targeted treatments for chronic conditions such as oncology, autoimmune diseases, or rare disorders.
For precise analysis, assume NDC 69315-0118 is a recently approved biologic addressing a high unmet medical need, characterized by complex manufacturing processes and high R&D costs, which traditionally influence pricing strategies.
Market landscape and demand drivers
1. Therapeutic Area and Patient Population
- Targeted Indications: The drug likely serves a small but growing patient base, especially in orphan or rare diseases sectors where treatment options are limited.
- Patient Demographics: Depending on the condition, the patient population may be concentrated geographically, with North America and Europe representing dominant markets due to healthcare infrastructure and reimbursement policies.
2. Market Size and Growth Potential
- Current Market Size: Given the specialization, initial market penetration may be modest, with estimates ranging from tens to hundreds of millions USD annually.
- Growth Drivers:
- Increasing diagnosis rates owing to improved screening.
- Broader indications approved via label expansion.
- Accelerated regulatory pathways for orphan drugs.
3. Competitive Environment
- Existing Alternatives: In the absence of direct competitors, the drug might enjoy a market exclusivity period, influencing initial pricing.
- Pipeline and Biosimilars: The emergence of biosimilars or generics post-expiry of patent protections could compress future prices.
- Partnerships & Licensing: Collaborations with biotech firms or large pharmaceutical companies could impact market access strategies and pricing.
Regulatory and Reimbursement Dynamics
1. Patent and Exclusivity Status
- If the product has secured patent protection, market entry barriers sustain pricing power.
- Orphan drug designation can extend market exclusivity, enabling premium pricing.
2. Pricing Regulations and Payer Policies
- U.S. Market: The Centers for Medicare & Medicaid Services (CMS), along with private insurers, influence reimbursement rates. The adoption of value-based pricing models and real-world evidence requirements may impact pricing strategies.
- International Markets: Countries like the UK, Germany, and Japan follow pricing negotiations through health authorities, often resulting in discounts and risk-sharing agreements.
Pricing Trends and Projections
1. Current Pricing Scenario
- Wholesale Acquisition Cost (WAC): As biologics tend to be priced high due to manufacturing complexity, initial WAC values likely range from $80,000 to over $200,000 annually per treatment course.
- List Price Volatility: Market access challenges and payer negotiations contribute to fluctuations, but premium positioning sustains high prices initially.
2. Short-term Price Outlook (Next 1-2 Years)
- Expect stabilization of early pricing strategies, reflecting the drug’s value proposition.
- Potential for initial discounts or rebates as market access broadens.
- Inclusion in value-based agreements could introduce price performance metrics.
3. Mid- to Long-term Price Projections (3-5 Years)
- Biosimilar Competition: Entry of biosimilars typically reduces biologic prices by 20-40%. If patent expiry occurs within 3-4 years, a significant price correction may ensue.
- Market Expansion & Label Extensions: New indications or higher dosing options might justify price adjustments upward.
- Regulatory and Policy Changes: Healthcare reforms focusing on cost containment could pressurize pricing, leading to negotiated discounts or prior authorization constraints.
Economic and Industry Factors Influencing Price Trajectory
- Manufacturing Costs: Advances in bioprocessing and increased production efficiency may facilitate cost reductions, enabling more competitive pricing.
- R&D and Launch Costs: High initial investments necessitate premium pricing to recoup expenses.
- Market Penetration Strategies: Direct-to-consumer marketing, strategic collaborations, and patient assistance programs influence uptake and revenue generation.
Key Influences on Future Price Projections
- Patent Life and Market Exclusivity: Critical determinants. Extended patent protection supports sustained premium pricing.
- Regulatory Labeling: Approvals for additional indications or higher dosing can influence revenue and pricing.
- Market Competition: Biosimilar entries and healthcare payer strategies will limit upfront pricing power.
Conclusion
For NDC 69315-0118, the current pricing environment reflects a typical specialty biologic with high initial prices driven by R&D costs, manufacturing complexity, and an unmet medical need. Short-term forecasts predict stable or slightly declining prices due to payer negotiations and competitive pressures. However, long-term projections hinge on patent protections, biosimilar market entrants, and regulatory developments.
Pricing strategies should adapt dynamically to these variables, emphasizing value-based care, real-world evidence, and negotiated access to maximize adoption and revenue potential.
Key Takeaways
- Premium Pricing Supported: High initial pricing is justified by research investment, manufacturing complexity, and limited competition.
- Market Entry of Biosimilars Likely to Drive Price Compression: Expect a 20-40% reduction post-patent expiry.
- Regulatory and Reimbursement Policies Will Shape Price Trajectory: Value-based agreements and coverage decisions are critical.
- Label Expansions and Indication Growth Can Increase Revenue and Support Pricing Power: Monitor regulatory filings for potential boosts.
- Manufacturing Innovations May Reduce Costs, Influencing Future Pricing Strategies: Companies should leverage process efficiencies to maintain competitiveness.
FAQs
1. What are the key factors influencing the price of NDC 69315-0118?
Main factors include manufacturing costs, patent protections, regulatory exclusivity, therapeutic value, competitive landscape, and payer negotiations.
2. How does biosimilar competition impact the drug’s price?
Biosimilars introduced post-patent expiry typically reduce biologic prices by approximately 20-40%, exerting downward pressure on revenue streams.
3. What regulatory policies could affect future pricing?
Regulations promoting value-based pricing, reimbursement frameworks, and potential importation or price caps in international markets can influence price trajectories.
4. Can label expansions increase the drug’s price or revenue?
Yes. New indications or higher dosing approvals often justify higher prices and expand the market, potentially increasing revenues.
5. What strategic considerations should manufacturers pursue to sustain pricing power?
Investing in clinical differentiation, demonstrating cost-effectiveness, expanding indications, and negotiating effective reimbursement agreements are crucial strategies.
References
- U.S. Food and Drug Administration (FDA). FDA Drug Approvals.
- IQVIA Institute. (2022). The Global Use of Medicines in 2022 and Beyond.
- RAND Corporation. (2021). Biosimilars in Healthcare: Market Dynamics and Pricing Trends.
- CMS. (2022). Medicare Part B Drug Pricing and Reimbursement Policies.
- Pharma Intelligence. (2023). Long-term Biologic Pricing and Market Outlooks.
More… ↓
